Therapeutic Response

EGFR Exon 19 (Deletion) status confers therapeutic sensitivity to Carboplatin in combination with Osimertinib in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Tagrisso (osimertinib) [product information]. EMA. The European Medicines Agency (EMA) has authorized osimertinib in combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions over exon 21 (L858R) substitution variants. This indication is based on the randomized, open-label, active-controlled trial FLAURA2 where the treatment arm with chemotherapy was investigator's choice of cisplatin (75 mg/m^2) or carboplatin (AUC).